C96.20 Code facturable et spécifique Malignant mast cell neoplasm, unspecified
ICD-10-CM C96.20 identifies “Malignant mast cell neoplasm, unspecified” as a billable/specific code in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapitre 2: Neoplasms
Instructions du code
Aucune note supplémentaire.
Instructions des niveaux supérieurs
Chapitres 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
C81-C96 · Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
C96 · Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
Excludes 11
personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues (Z85.79)
C96.2 · Malignant mast cell neoplasm
Références de l’index officiel
Références de l’index officiel (2)
Mast cell (1)
- Mast cell › neoplasm › malignantIndex des maladies
Neoplasm, neoplastic (1)
- Neoplasm, neoplastic › malignant mast cellIndex des maladies
Historique officiel de conversion
Historical assignments from the CDC conversion table support data retrieval. They do not authorize substituting a previous code for the current code.
Attribution précédente: C96.2
Historique
Historique du code
Dernière modification enregistrée · FY2018
En vigueur dès le
- Ajouté
Malignant mast cell neoplasm, unspecified
Code de diagnostic facturable
CDC/NCHS · FY2018Toutes les éditions (17)
| Toutes les éditions | En vigueur dès le | Historique du code |
|---|---|---|
| FY2018 | 2017-10-01 | Ajouté |
| FY2019 | 2018-10-01 | Aucun changement tabulaire |
| FY2020 | 2019-10-01 | Aucun changement tabulaire |
| FY2020 · April | 2020-04-01 | Aucun changement tabulaire |
| FY2021 | 2020-10-01 | Aucun changement tabulaire |
| FY2021 · 01-01 | 2021-01-01 | Aucun changement tabulaire |
| FY2022 | 2021-10-01 | Aucun changement tabulaire |
| FY2022 · 04-01 | 2022-04-01 | Aucun changement tabulaire |
| FY2023 | 2022-10-01 | Aucun changement tabulaire |
| FY2023 · 04-01 | 2023-04-01 | Aucun changement tabulaire |
| FY2024 | 2023-10-01 | Aucun changement tabulaire |
| FY2024 · 04-01 | 2024-04-01 | Aucun changement tabulaire |
| FY2025 | 2024-10-01 | Aucun changement tabulaire |
| FY2025 · 04-01 | 2025-04-01 | Aucun changement tabulaire |
| FY2026 | 2025-10-01 | Aucun changement tabulaire |
| FY2026 · April | 2026-04-01 | Aucun changement tabulaire |
| FY2027 | 2026-10-01 | Aucun changement tabulaire |
Correspondances ICD-9 historiques · 2018
Correspondance historique uniquement ; pas de substitution automatique.
- 202.60 · Approximative
- 202.61 · Approximative
- 202.62 · Approximative
- 202.63 · Approximative
- 202.64 · Approximative
- 202.65 · Approximative
- 202.66 · Approximative
- 202.67 · Approximative
- 202.68 · Approximative
Cette entrée est un code complet dans l’édition sélectionnée. La vérification du référentiel ne confirme pas la pertinence clinique et ne garantit pas le remboursement.